2025³â 02¿ù 01ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

IMCAS 2025: Galderma¡¯s Broad Presence and New Data on Recently Launched Products Restylane SHAYPE and Relfydess

´º½ºÀÏÀÚ: 2025-02-01

ZUG, SWITZERLAND -- Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 - February 1 in Paris, France. The company will share ten research e-posters with data that differentiate its injectable aesthetic products, including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Masterclass, five Meet the Expert sessions, and an interactive booth focused on the power of Relfydess.

“With such an extensive presence at the IMCAS congress this year, we have another opportunity not only to share the latest advancements from our broad and innovative injectable aesthetics portfolio, but also to connect with the community in a meaningful way, through information sharing and insights gathering. Our offering at IMCAS brings our Integrated Dermatology Strategy to life, differentiates our products, and cements Galderma as the category leader in dermatology.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA

Extensive data updates from across the industry’s broadest Injectable Aesthetics portfolio

New data will include results from the phase IIIb RELAX study investigating the long-term aesthetic improvement and subject satisfaction over 12 months following a single dose of Relfydess in patients with moderate-to-severe frown lines.[15] This study reinforces previously announced data from the READY clinical trial program, demonstrating that up to 39% of patients see effects from day one and up to 75% of patients maintain improvements for six months for frown lines and crow’s feet when treated with Relfydess.[3,4,7]

Additional findings will further reinforce the scientific differentiation of Relfydess, including data adding to the effect of Galderma’s proprietary PEARL Technology process on preserving molecule integrity, and showing no neutralizing antibody formation across Relfydess’ phase III program.[16,17] A pooled post-hoc analysis from the READY-1-3 trials will also be presented, affirming the efficacy of Relfydess across more than 1,700 patients with diverse skin types, ethnicities, and races.[18]

In addition, a symposium titled ‘Go beyond with Relfydess: Step into the future’ will take place on Friday, January 31, from 2:00 - 3:30 PM CET, in Grand Amphi, and will showcase the clinical performance and innovative volumetric approach of Relfydess, featuring a live injection demonstration. At the Galderma booth - #L212 - experts will also dig deeper into the cutting-edge science behind Relfydess and PEARL Technology.

Galderma will also present the latest data on Sculptra, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation.[8-12] New data reinforce its robust regenerative properties and effects across all three skin layers, underscoring its key role in the regenerative aesthetics field, including its benefit in comparison to other products.[19-21] Studies suggested Sculptra stimulated the key components of the skin, including collagen, elastin and adipose tissue, and reinforced its favorable safety profile.[19-21] An additional comparative study found synergistic effects for the midface when pairing Sculptra with Alastin®, with an improvement in aging skin and patient experience when using both.[22]

New pooled data from three Galderma studies of the Restylane portfolio will be presented, demonstrating that treatments with Restylane Refyne™ and Restylane Defyne™ not only enhance attractiveness and youthfulness, but also preserve naturalness of both relaxed and dynamic facial expressions.[23] Additionally, gel data for Restylane SHAYPE - the latest addition to the broadest hyaluronic acid (HA) portfolio, which is powered by Galderma’s innovative NASHA HD Technology with improved crosslinking efficiency and increased HA content - reveal it has the highest G-prime among commonly used HA fillers, indicating superior gel strength and firmness, making it ideal for lower face shaping.[14]

Connecting with the dermatology community

Beyond sharing the latest data, the IMCAS World Congress also represents an important opportunity to connect with the broader dermatology community in order to facilitate best practice sharing and gather crucial insights to guide future innovation. The Galderma Aesthetic Injector Network (GAIN) - which celebrates its 10th anniversary this year - is Galderma’s long-established training platform designed to educate, inspire, and empower through the creation of a unique community of highly trained, clinically proficient aesthetic practitioners. As part of this enduring commitment to the community, Galderma will host a symposium at the congress titled ‘GAIN Debates: Crafting Our Aesthetic Lives - Prioritization for Impactful Treatment’, taking place Friday, January 31, from 10:30 AM - 12:30 PM CET in Amphi Bleu. A separate medical symposium titled ‘Innovation by Galderma: Where Aesthetics Meets Science’ will also be held on Friday, January 31 from 9:00 - 10:00 AM CET in Regency 3+4 on Level 4.

Galderma will also run a Masterclass session on using injectables to address the specific aesthetic needs related to the effects of medication-driven weight loss, taking place on Thursday, January 30 from 2:00 - 4:00 PM CET in Salon d’honneur. Five Meet the Expert sessions will also further reinforce Galderma’s unique position as a leader in dermatology. The sessions will explore topics including Skin Quality, end-to-end collagen and elastin stimulation, and redefining HA fillers to create natural looking results, and will dig deeper into Alastin, Sculptra, and Relfydess as part of these discussions. The events will be held at the Galderma booth and live streamed on the @GAINbyGalderma Instagram profile.



 Àüü´º½º¸ñ·ÏÀ¸·Î

The Future of Electrification Conference Returns for its Fourth Year
Sparkle Clean Tech Licenses Oil & Gas Water Treatment Technologies from Siemens Energy, Inc.
IMCAS 2025: Galderma¡¯s Broad Presence and New Data on Recently Launched Products Restylane SHAYPE and Relfydess
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Diligent Announced Market Insights Reporting Powered by S&P Global Market Intelligence, Offering Directors and Executives Unrivaled Financial and Risk
Rimini Street Announced Rimini Protect¢â Advanced Hypervisor Security for VMware, Nutanix and All Other Linux-Based Hypervisors
Cognite Recognized as a Leader in Industrial Data Management Solutions

 

GCT Semiconductor Participates in Exclusive Aramco Digital and 450 MHz...
Novotech Releases Report on Current State of Triple-Negative Breast Ca...
FDA Authorizes All ZYN Nicotine Pouch Products Currently Marketed by S...
Access Advance Announces Video Distribution Patent Pool in Response to...
Cyble Recognized in Extended Threat Intelligence Service Providers Lan...
Galderma Premieres Positive Interim Results Demonstrating the Efficacy...
Bynder Showcases Its New and Expanded AI Capabilities at NRF to Help R...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..